IC
NKTR icon

IEQ Capital’s Nektar Therapeutics NKTR Stock Holding History

IEQ Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-38,255
Closed -$989K – 2002
2025
Q2 		$989K Buy
38,255
+1,107
+3% +$12.4K 0.01% 866
2025
Q1 		$379K Buy
37,148
+35,683
+2,436% +$466K ﹤0.01% 1096
2024
Q4 		$20.4K Hold
1,465
– – ﹤0.01% 1320
2024
Q3 		$28.6K Hold
1,465
– – ﹤0.01% 1143
2024
Q2 		$27.3K Sell
1,465
-145
-9% -$3.06K ﹤0.01% 986
2024
Q1 		$22.6K Buy
1,610
+704
+78% +$7.37K ﹤0.01% 963
2023
Q4 		$7.68K Buy
906
+133
+17% +$1.01K ﹤0.01% 924
2023
Q3 		$6.91K Hold
773
– – ﹤0.01% 937
2023
Q2 		$6.67K Hold
773
– – ﹤0.01% 896
2023
Q1 		$8.15K Hold
773
– – ﹤0.01% 888
2022
Q4 		$26.2K Sell
773
-3,786
-83% -$183K ﹤0.01% 805
2022
Q3 		$219K Sell
4,559
-300
-6% -$17.8K 0.01% 747
2022
Q2 		$277K Sell
4,859
-26
-0.5% -$1.64K 0.01% 624
2022
Q1 		$395K Buy
4,885
+15
+0.3% +$2.22K 0.01% 563
2021
Q4 		$987K Buy
4,870
+3,779
+346% +$820K 0.02% 310
2021
Q3 		$294K Buy
+1,091
New +$262K 0.01% 562
2021
Q1 		– Sell
-17,771
Closed -$4.53M – 491
2020
Q4 		$4.53M Buy
+17,771
New +$4.59M 0.2% 83

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IEQ Capital's NKTR Position: Q3 2025 in Review

IEQ Capital sold out of Nektar Therapeutics (NKTR) in Q3 2025, closing a stake of 38,255 shares — an estimated $989K sold.

IEQ Capital first reported a position in NKTR in Q4 2020 and held it in 17 quarters. The position peaked at $4.53M in Q4 2020. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • IEQ Capital reported no remaining Nektar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • IEQ Capital sold 38,255 Nektar Therapeutics shares in Q3 2025, an estimated $989K.
  • IEQ Capital first reported a position in Nektar Therapeutics in Q4 2020 and held it in 17 quarters.
  • IEQ Capital's Nektar Therapeutics position peaked at $4.53M in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on IEQ Capital's 13F filing for Q3 2025, filed 14 Nov 2025.